The new creation: An update on animal gene engineering by Fox, Michael W.
Michael W. Fox
Vice President, Bioethics and Farm Animals 
The Humane Society of the United States
The New Creation:
An Update on Animal Gene Engineering
here have been several new developments in genetic engineering that
show how this new industry is applying biotechnology in agriculture 
and medicine. How valuable these new developments are—in terms of real 
progress in improving agricultural practices and human health—remains to 
be seen. The following examples clearly reveal that the “New Creation” and 
new world order of the biotechnology industry is far from any utopian dream 
of a world made perfect for humankind. One can read between the lines of 
the new patent applications, news releases and scientific reports concerning 
the latest feats of genetic engineering and glimpse into the future. The won-
der-world of the New Creation is not quite here today, but it may be upon us 
sooner than we expect. A whole new generation of genetically engineered 
(so-called transgenic) animals is on the horizon. These will carry genes taken 
from humans and other species. In the world of trade and commerce, they 
will be regarded as “new” species—unique, patentable commodities of the 
new world order.
T R A N S G E N I C  A N I M A L S
Scientists in the U.S., Japan, Europe and Australia have created a number of 
transgenic animals—pigs, lambs, calves and fish—containing the genes of 
other species like the human and bovine growth hormone genes. Success 
rates of gene insertion are extremely low and the entire process is time con-
suming and costly. Much of the funding in this area of biotechnology comes 
from the public via government tax revenues.
Some researchers have recently opted to put extra growth-regulating 
genes of sheep origin into lambs rather than human genes because they felt 
that “transgenes composed entirely of sheep gene sequences would be more 
acceptable to lay persons, in particular consumers” (Murray and Rexroad, 
1991). However, even though these lambs were leaner, they did not have in-
creased feed efficiency. They were diabetic and had such severe health prob-
lems that they died before reaching puberty. “The cause of death has varied, 
but there are clear data that the over-expression of GH (growth hormone)
adversely affects liver, kidney and cardiac function” (Murray and Rexroad, 
1991).
Merck & Co., the European-based pharmaceutical company, has applied 
for a patent in Europe on its super chicken, or Macro-Chicken (Holden, 
1991). They have developed a line of broiler chickens that carry the growth 
gene of cows with the hopes of cornering the market with a highly feed-effi-
cient, fast-growing bird.
It is likely that Merck’s Macro-Chickens will have a variety of health 
problems too. But if the birds eat well and grow quickly, they will be ready for 
slaughter before severe health problems ever develop. But what of the breed-
ing stock of transgenic chickens that will not be raised for slaughter? Will 
they suffer? Because such information is proprietary, corporations are not 
likely to reveal the limitations and risks of their new patentable creations. 
Trade secrets notwithstanding, the social and economic consequences—to 
farmers, to the practice and structure of agriculture and to consumers—of 
creating transgenic farm animals have been given scant attention.
Critics of the genetic engineering of farm animals question the use of 
public funds to make these animals produce more meat (even if it is lean) 
when the short- and long-term costs of such research are not considered and 
when a major problem of contemporary intensive animal agriculture is over-
production, meat and milk surpluses being a chronic problem. It is unlikely 
that the creation of transgenic farm animals will help feed the hungry world 
since meat production efficiency has built-in limitations and inevitable envi-
ronmental costs (Durning and Brough, 1991; Fox, 1990).
Genetic engineering technology is being used in an attempt to alter 
sheep’s and cows’ milk so that it can be consumed by a large percent of the 
world population that is lactose-intolerant (Mercier, 1987). This may be a 
more fruitful approach to helping feed the hungry, since milk production is 
far more efficient, ecologically sound and cost-effective than meat produc-
tion, with or without biotechnology.
Human genes responsible for the production of proteins in mothers’ 
milk are being inserted into calf embryos with the hope of creating a new 
generation of cows that produce “humanized” milk (Phelps, 1989).
Australian government scientists are using genetic engineering to make 
sheep produce more wool by inserting genes into their developing embryos. 
The sheep’s body chemistry is altered to convert sulfur-bearing compounds 
into methionine, an amino acid that increases wool growth (Ford, 1988). 
Australian scientists are also trying to genetically engineer a hormone that 
can be injected into sheep that will make them shed their fleece, thus cutting 
down costs of shearing. Tests to date have caused pregnant sheep to abort 
(Scherer, 1992; New Scientist, 1992). They also plan to genetically engineer 
sheep that secrete insect repellent from their hair follicles to ward off blow-
flies. Blowflies cost the sheep industry $85 million per year in losses. As a 
spinoff, the sheep will also have the world’s first moth-proof wool.
Animal Biotechnology: Opportunities & Challenges
It should be emphasized that most genetic engineering research in farm 
animals has focused on increasing productivity, while research on increasing 
resistance to disease through genetic engineering (Slater, 1990; Kraemer and 
Templeton, 1990) is still very much in its infancy. This latter area of research 
should be questioned since improvements in farm animal husbandry are 
surely more cost-effective ways of improving animal health and well-being.
T R A N S G E N I C  “ M O L E C U L A R  P H A R M I N G ”
Human genes are being inserted into farm animals so that they produce vari-
ous pharmaceutical products in their milk, such as blood clotting factors and 
other substances of possible medical application (Clark et al., 1987; Watts, 
1990; Schanbacher, 1990; Bialy, 1991). Harvey Bialy, editor of Bio/Technology, 
has extolled the virtues of what he terms “molecular pharming technologies,” 
as exemplified by research teams from the UK, U.S. and The Netherlands, 
who have produced transgenic sheep whose milk contains human alpha-1- 
antitrypsin, transgenic goats that secrete tPA into their milk and the first 
transgenic dairy cattle. “Taken together,” he writes, “their results provide a 
convincing demonstration of the feasibility of using animals as commercial 
bioreactors” (Bialy, 1991). It will be many years before these new animal cre-
ations provide any medical benefits to humans, but venture capitalists are in-
vesting in this speculative line of research and development. Recently, a bio-
technology company, DNX Inc., of Princeton, New Jersey, reported that it has 
developed a line of transgenic pigs that produce human hemoglobin. But they 
are still a long way from having hog farmers raise pigs to be human blood do-
nors (Moffat, 1991a).
O T H E R  I N N O V A T I O N S
Other developments in farm animal biotechnology (which do not entail gene 
transfer) that can have profound social and economic ramifications include 
the development of cow clones (Schmickly, 1991) and a technique to preselect 
the sex of offspring (Federal Register, January 10, 1991). Scientists are baffled 
over the fact that some 25 percent of calves produced by cloning are almost 
twice the normal size at the time of birth and must therefore be delivered by 
Caesarian section.
While no plant genes have been inserted into animals, animal genes have 
been successfully incorporated into the genetic structure of various plants. 
Tobacco plants have been successfully implanted to produce functional hu-
man antibodies, which may be used for diagnosing and treating human dis-
eases. The “antifreeze” gene of the flounder that produces a protein to stop the 
fish from freezing, has been cloned and inserted into tomatoes and tobacco; crops 
may be protected from frost in the future by fish genes (Moffat, 1991b).
Since fish farming is on the increase, biotechnologists have been busy de-
veloping “superfish,” by inserting growth hormone genes from humans, 
cattle, chickens, mice and other fish into a variety of commercially raised fish,
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such as carp, rainbow trout, catfish, Atlantic salmon, walleye and northern 
pike. The antifreeze gene of the winter flounder is also being inserted into 
other fish species to expand commercial fish production in cold regions and 
seasons (New York Times, November 27, 1990; Manci, 1989; Biotechnology 
and Development Monitor, 1991; Fischetti, 1991).
A biotechnologist at the Army Research Laboratory in Natick, Massa-
chusetts, has cloned the silk-producing gene of the Golden Orb weaver spi-
der and spliced it into bacteria that in turn produce large quantities of spider 
silk protein. Stronger than silkworm silk and even steel, this new product 
may have wide commercial use, especially to develop new fabric for bullet 
proof vests, helmets, parachute cords and other strong, light equipment 
(AP news release,.February 27,1990).
On the brave new world frontier of medicine, scientists have created a 
variety of transgenic mice. Some thirty or more strains of mice have been 
created that develop various kinds of cancers that affect the mammary 
glands, pancreas, liver, stomach, bones, brain, eyes and kidneys (Adams and 
Cory, 1992). Another line of mice have been created that carry human genes 
that result in deformed red blood cells, providing a new model for sickle-cell 
anemia (Genetic Engineering News, June, 1991), and a line of rats have been 
developed that carry the defective human gene HLA-B27 that causes a pain-
fully crippling form of arthritis (Fackelmann, 1990). The clinical relevance of 
these new creations has yet to be demonstrated. Making them transgenic pro-
vides no foreseeable benefit to the animals themselves, except perhaps for en-
dangered and genetically “fragile” or defective species, like the cheetah and 
South American maned wolf.
Research is continuing on the identification of genes responsible for 
various inherited diseases, especially in purebred dogs and livestock and on 
genes that play a role in development, growth, milk and egg production, dis-
ease resistance and other physiological processes. The results of such costly 
research may eventually be of benefit to animals in terms of their health and 
overall well-being. But the benefits will be limited if this approach becomes 
overly reductionistic and utilitarian and is not integrated with a more holis-
tic, if not traditional, approach to improving animal health and well-being. 
And especially if it is focused primarily on enhancing the exploitative value 
of animals.
The human genome is being sequenced and genetic defects and strengths 
identified. Next will be the cow, the pig and the dog. All to what end? New 
medical and veterinary products and services will certainly result, including 
varieties of more productive and disease-resistant livestock. But genetic de-
terminism can lead ultimately to eugenics. And eugenics means genetic im-
perialism and a new world order for a New Creation. Do we really want or 
need a Creation made over into a human image of perfect utility?
Animal Biotechnology.- Opportunities & Challenges
N E W  A N I M A L  D R U G S
One potential benefit of biotechnology to animals is in the development of 
genetically engineered vaccines (including birth-control vaccines), hormones, 
immune system enhancers and diagnostic and screening tests. However, this 
new generation of veterinary products and services may be a mixed blessing. 
It is not without potentially adverse animal health, socioeconomic and eco-
logical consequences-as with BST or bovine growth hormone (Wheale and 
McNally, 1990; Gendel, 1990). Many of these products are no substitute for 
humane animal husbandry, sound breeding and good nutrition. There is also 
some evidence that genetically engineered, modified live virus vaccines may 
play a role in the development of autoimmune diseases, especially in pure-
bred dogs (Dodds, 1990).
P U B L I C  A T T I T U D E S
While private industry and government-funded research centers push for-
ward to create genetically engineered animals that may prove profitable 
to agribusiness and the medical-industrial complex, the public’s attitude 
toward such developments is noteworthy. In a recent poll across Europe:
fewer than half thought biotechnological research on farm 
animals “to make them resistant to disease, or grow faster” 
should be encouraged. A third thought, applying biotechnology 
to animals “to develop life-saving drugs or study human dis-
eases” was morally acceptable, “provided the animals’ wel-
fare is safeguarded,” but 20 percent said it was morally wrong 
and 27 percent said government should decide each case. Only 
13percent thought such work justified“some animal suffering” 
(Mackenzie, 1991).
A national survey in Japan revealed that 67 percent of people polled were 
opposed to research that could lead to new forms of plant or animal life 
(Holden, 1988). Opinion polls in the U.S. show that in 1985, 34 percent of 
the attentive (informed) public wished to prohibit the creation of new forms 
of animal and plant life (Feinstein and Miller, 1991). A recent survey in The 
Netherlands finds that consumers “are very unhappy about eating meat from 
genetically engineered animals. They are either afraid it will harm them or 
worried about it on ethical grounds” (Coghan, 1991).
A N I M A L  P A T E N T I N G
The controversy over the patenting of genetically engineered animals began 
after the U.S. Patent and Trademark Office ruled on April 7, 1987, that such 
animals, provided they were nonnaturally occurring “manufactures” and 
“compositions of matter” could be included under Section 101 of the Patent
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Act as patentable subject matter. The patenting of animals was vigorously 
opposed by The Humane Society of the United States (HSUS) and a coalition 
of concerned organizations. On August 5, 1987, Representative Charles Rose 
introduced legislation (HR 3119) to impose a moratorium on the patenting 
of animals so that the potential adverse implications of such patenting could 
be carefully studied. And on February 29, 1988, Senator Mark Hatfield intro-
duced moratorium bill S 2111 in the Senate. But on April 13,1988, the U.S. 
Patent Office and Trademark Office issued Patent Number 4,736,866 on 
Harvard University’s, DuPont Chemical Co. funded, new creation—the 
“Onco Mouse,” a genetically engineered, cancer-prone mouse (Hubbard and 
Krimsky, 1991).
Since this time, there have been no further animal patents awarded, even 
though the U.S. government and U.S.-based multinational corporations have 
been pushing for changes in European patent law that currently prohibits the 
patenting of animals (Watts, 1991); and even though the State Department 
effectively squashed the Rose and Hatfield bills on the grounds that they 
would weaken U.S. economic competitiveness in the world marketplace.
Some 145 patent applications are now awaiting approval at the U.S. 
Patent and Trademark Office. Approximately 80 percent of these have medi-
cal utility while the remainder involve agricultural animals (Congressional 
Record-Senate, June 13, 1991). One explanation for the fact that no new ani-
mal patents have been awarded is that there is as yet no clear regulatory 
structure set up for the commercial marketing of transgenic animals 
(Charles, 1991; Fox, 1991).
A new bill was introduced in the Senate (S 1291) by Senator Hatfield on 
June 13,1991, to impose a 5-year moratorium on the granting of patents on 
invertebrate and vertebrate animals including those that have been geneti-
cally engineered. HSUS supported this bill with the following statement pub-
lished in the Congressional Record on that day;
In order for society to reap the full benefits of advances in 
genetic engineering biotechnology, the social, economic, 
environmental and ethical ramifications and consequences 
of such advances need to be fully assessed. Considering the 
rapid pace of developments in this field, which will be spurred 
on by the granting of patents on genetically altered animals, 
a 5-year moratorium on the granting of such patents is a wise 
and necessary decision. A moratorium will enable Congress 
to fully assess, consider and respond to the economic, envi-
ronmental and ethical issues raised by the patenting of such 
animals and in the process, establish the United States as the 
world leader in the safe, appropriate and ethical applications 
of genetic engineering biotechnology for the benefit of so-
ciety and for generations to come (pp. 7818-19).
It is very likely that the Council on Competitiveness, chaired by Vice Presi-
dent Dan Quayle, will attempt to block this bill. This same Council has been
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actively working to deregulate the entire biotechnology industry. Its pro-
posed administrative and regulatory guidelines for the Environmental Pro-
tection Agency and U.S. Department of Agriculture are such that the risks 
and costs of new biotechnologies—socially, economically, environmentally 
and in terms of animal-welfare—will be virtually ignored (Charles, 1991;
Fox, 1991).
Clearly, while the genetic engineering of animals is not likely to be 
stopped, increasing public awareness and censure of the biotechnology in-
dustry and its political allies is essential. A 5-year moratorium on the patent-
ing of “new” animal creations would be prudent and timely, especially since 
we are moving into a new world order of free trade, which should be condi-
tional upon effective international regulations and the adoption of the most 
stringent controls and regulations over biotechnology by all nations. Other-
wise, the privatization of the world’s resources and of the genetic material of 
life itself, coupled with the misapplication of genetic engineering biotechnol-
ogy in agriculture and medicine, will be against the public interest and the 
good of generations to come.
C O N C L U S I O N
There are several interrelated dimensions to fully evaluating the costs and 
consequences, risk and benefits of new developments in science, technology 
and industry, especially in genetic engineering biotechnology; and of the pat-
enting of both processes and products. These dimensions are as follows: 
ethical and religious, legal and political, social and economic, environmental 
and cultural. Generally these dimensions of concern, constraint and direc-
tion have been virtually ignored by policy-makers and even seen as obstacles 
to economic growth and industrial expansion. As a consequence, the gap has 
widened between private (corporate) and public interests. We are witness to 
a widening of this gap with the rise of a global industrial biotechnocracy, the 
costs and consequences, risks and benefits of which need to be rigorously 
evaluated. To voice such concern should not be misjudged as anti-science, 
anti-progress. Rather, it should be recognized that with greater involvement 
of an informed public in the policy decision-making process, advances in 
science and technology and in biotechnology in particular, will be more 
likely to serve the public good and to help enhance the quality of life and en-
vironment alike. Current attempts by the U.S. government to deregulate the 
biotechnology industry (Phelps, 1991) and by the EEC’s Commission on Bio-
technology to eliminate socio-economic considerations in the licensing of 
new animal drugs (Phelps, 1991) support the conclusion that the direction 
being taken by the biotechnocracy of the industrialized world is neither prudent 
nor appropriate.
Some proponents of genetic engineering feel “more comfortable” (from 
a not fully articulated moral/ethical perspective) with the patenting of the 
techniques of biotechnology, rather than with its products, including transgenic
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animals. However, the unconditional acceptance of creating transgenic ani-
mals for any and all purposes (from the perspective that it is not a moral/ 
ethical issue to create such animals) is as unreasonable as the unrealistic abo-
litionist position that would prohibit all such research and development 
(because it is immoral/unethical).
Our power over the genes of life is a recent acquisition, as significant a 
notch in human evolution as the discovery of pyrotechnology and atomic en-
ergy. But this power does not give U.S. the absolute right to transform ani-
mals to further satisfy our myriad needs and wants. Rather, it places U.S. on a 
critical threshold of moral/ethical choice and responsibility. This means that 
we must choose wisely and compassionately, case by case. We must not forget 
the history of science, technology and industry. In the past, we have made 
many wrong choices for selfish reasons, the consequences of which have been 
as harmful to our own kind as to the rest of Creation, especially to the animal 
kingdom and to the natural biodiversity of our fragile planetary ecosystem.
A D D E N D U M
First Creation-First:
Protecting the First Creation from Further 
Desecration and Transformation
The kinds of plants and animals that are being genetically engineered for agriculture (along with a host of other agribiotechnology products) are 
primarily those kinds that are being designed for adoption by conventional 
agriculture. Their adoption and incorporation into our food production sys-
tem should be contingent upon them quickly helping make industrial agri-
culture humane and sustainable.
The appropriate use of agribiotechnologies in ecological farming, in ho-
listic resource management and in the development of alternative, socially 
just agriculture is possible and attainable. It should not be used as another 
technological fix to compensate for the effects of agricultural degradation, 
but at the same time aggravate that degradation, necessitating even more 
costly “fixes.” It is surely absurd to use this technology to boost productivity 
of agricultural commodities that are already in oversupply, like milk.
Genetically engineered bovine growth hormone (BGH)—which is an af-
front to the science and ethics of good dairy cow husbandry—is the first 
product that the biotechnology industry has yet to recognize as their own 
Ford Edsel: And selling it to good dairy farmers is like convincing Eskimos 
that they need refrigerators.
Increased dependence upon biotechnology will put us on the treadmill 
of economic competitiveness accelerating the transformation of life into 
profitable commodities, with the emergence of genetic imperialism and an
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increasingly p arasitic relationship with the rest of Earth’s creation, as exem-
plified by turning farm animals into bioreactors to produce pharmaceuticals.
Another example of gross misapplication of biotechnology would be to 
develop a vaccine to make African cattle resistant to Trypanosomiasis rather 
than using this new technology to increase overall herd health and productiv-
ity and indirectly reduce herd size. Such a vaccine would lead to an expansion 
of livestock into wildlife areas (where wild animals possess natural immu-
nity) and will mean the end of the wild.
While the benefits to animals of making them transgenic are unclear, 
there are clear benefits of other biotechnologies to enhancing their overall 
well-being. These include: rapid identification and elimination of genetic 
diseases; increased disease resistance; protection of endangered species; hu-
mane population control of feral and wild species; preservation of genetic di-
versity; selecting farm animals better adapted to traditional, and alternative, 
humane husbandry systems; increased efficiency/productivity of farm ani-
mals, which will mean fewer animals, more efficient resource utilization and 
more land being freed up for wildlife habitat recovery.
Appropriate uses of biotechnology in animals should follow the “3R’s” of 
refinement, reduction and replacement in the utilization of animals by society 
today. We need to not only decrease the suffering and enhance the well-being 
of animals utilized by society today, we also need to decrease and not increase 
our dependence upon them for a host of reasons—economical, ethical, envi-
ronmental, etc. For detailed discussion see Fox, 1992.
Gene mapping and marker-assisted selection to identify useful genes in 
cattle, hogs and poultry should not be focused primarily on making these 
animals more productive under conventional husbandry conditions. Over-
production is a chronic and unacceptable problem, lowering farmers’ profits 
and forcing them to get bigger or get out. Better to seek genes that will help 
livestock and poultry be healthier and better adapted to more ecologically 
sound farming practices, like rotational grazing of dairy cows and pasture 
feeding of hogs and helping the livestock population in the Third World cease 
to expand and to become healthier and more productive. Better still, per-
haps, to conserve and propagate rare breeds for such purposes than to create 
patented transgenic animals derived from narrow utility stock genetically se-
lected for generations to be used under intensive factory systems of produc-
tion that are gaining widespread societal disapproval.
Above all, new developments in biotechnology should not create barriers 
that would prevent or delay the adoption of alternatives, such as more hu-
mane sustainable animal husbandry practices and greater advances in public 
health, education and nutrition instead of creating ever more transgenic 
mice. With these considerations and caveats, the appropriate application of 
biotechnology in animals will be more reasonably assured and objectively 
determined.
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The biotechnology explosion has resulted, over the past decade, in the 
creation of over 10,000 new lines of transgenic mice; in farm animals with 
human genes producing milk with new health promises to offer genetically 
impaired and immune-compromised people; in genetically engineered 
plants secreting spider venom. Human disease antigen injected into cows to 
provide day care infants and others with protection from the diseases that are 
spread and potentiated by their situation may soon be marketed. Milk con-
tains a natural opiate, which may help calm some kids down. Selecting cows 
to produce opiate-rich “Sleepy Time” milk may be on the horizon soon. Al-
ready there is a company developing a transgenic pig industry to provide “xe-
nografts”—genetically humanized swine hearts, livers and kidneys—for hu-
mans in need of such organ transplants.
These new directions and applications of biotechnology make one won-
der when there will be a concerted effort to develop and distribute a safe and 
effective, if not also a reversible, genetically engineered contraceptive. That it 
will be developed and marketed for women first should not be an obstacle to 
its widespread adoption. The Catholic Church could help by embracing the 
view that such an application of biotechnology is to use our God-given 
power over the gene for reasons of compassion and to further the greater 
good and future security of all Creation.
We must stop multiplying our numbers, needs and wants. And we must 
learn to live gently and simply so that others may simply live. We need to stop 
regarding technological progress as unstoppable. It is change that we cannot 
stop; and it is up to us to direct progress, to take charge of the direction new 
technologies might take in order to maximize their benefits and minimize 
their costs and risks to all concerned. We need to constantly redefine what true 
progress is in order to implement correctives and preventatives where needed.
The mutant “monster” creation of genetic engineering we all feared has 
already been created and released into the world. It is not some insulation-
eating superbug, AIDS-like virus, mind-altering transgenic pollen, or Iowa 
corn plant that eats Texas beef. This monster seeks to use biotechnology for 
purely materialistic and consumptive ends and is preparing to remake cre-
ation into its own image of how the natural world can best serve its myriad 
consumptive needs.
The primary purpose behind the genetic engineering of Second Creation 
products is their profitability to their makers: the remakers of the First Cre-
ation. The mythic image of this mutant monster that connects us to a fate far 
more terrible than that of a Midas, Icarus, Prometheus or Marsyas, is so be-
cause it consumes itself as it destroys the Earth’s natural resources.
After the carnage, the pestilence, the long drought, the ozone hole, 
Chernobyl, pesticide rain and shores reeking with dead seals and dolphins, what 
will there be? What is coming is what we see, unfolding before our very eyes.
Genetic engineering and all applicable technologies should first and 
foremost be directed at these kinds of issues and with the vision and ethics of
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organic, if not sacred, unity rather than at developing new biotechnology 
products to help boost a non-sustainable agricultural system and an unethi-
cal biomedical research industry. The so-called health industry fights cancer 
with tons of profitable treatment, but not an ounce of prevention and justi-
fies untold animal suffering in the name of medical progress.
How can we have a government with health and agricultural agencies 
that are not in concert, but in kahoots? For them to prohibit the wholesale 
application of thousands of potential carcinogenic chemical pesticides and 
the millions of tons of petrochemical fertilizers by the feed and food industry 
would be in the public interest. So why has this not been done and countless 
other social and ethical issues addressed by industrial world governments? 
Perhaps not until we all confront our own personal monsters and demons 
and discover that we are all related.
We cannot continue to be blind to the irony that there are many publicly 
supported corporations that are distributing pesticides, as well as processing 
and marketing various crops and factory-farmed animals; developing and 
patenting genetically engineered mice and selling x-ray film for nationwide, 
annual mammograms.
The monster on this planet is a product of biotechnology because in 
breaking the DNA code, it became addicted to changing the codes of life to 
serve its own industriously Earth-transforming and all-consuming existence.
The male of this monstrous product of biotechnological skill and arro-
gance likes those of its opposite sex to have large firm breasts. It even sells 
them breast implants when their natural breasts become cancerous with the 
poisons of industrial indifference, ignorance and greed.
The entire immune system within the monster body-human, the corpus 
of industrial civilization, is beginning to break down. It is creating thousands 
of varieties of transgenic mice to find ways to help its failing immune system 
adapt to an increasingly dysfunctional and hazardous society and environ-
ment. The monster’s name is Nemesis. His mate, more ignorant than Eve and 
not so loving and alive, is a modern Pandora with perfect silicone breasts.
Where nature is the least defiled, humans still go to rest, dream, heal, 
play and pray. But some still come to these sacred places—the dying rem-
nants of the First Creation—simply to take. They must be stopped by all and 
every means for our children’s sake and for all other creatures great and small.
To conclude, from an ethical and spiritual perspective, the future of the 
natural world or First Creation will only be secure if this new technology is 
applied like no other before it. Otherwise, the Second Creation will mean a 
wholly unnatural, humanized world as we transform the First Creation into a 
bioindustrial system remade into our own self-serving materialistic image of 
utility and productive efficiency.
R E F E R E N C E S
Adams, J.M. and S. Cory. 1992. Transgenic models of tumor development.
Science. 254:1161-64.
The New Creation
AP News Release. 1990. Army’s gene-spliced spider silk may prove 
superfabric of future. Boston. February 27.
Bialy, H. 1991. Transgenic pharming comes of age. Bio/Technology. 9:786-88.
Biotechnology and Development Monitor. 1991. Biotechnology in fishfarms: 
Integrated farming or transgenic fish? 7:3-6.
Charles, D. 1991. White House changes rules for genetic engineering. New 
Scientist, May 25, p. 14.
Clark, A.J., P. Simons, I. Wilmut and R. Lathe. 1987. Pharmaceuticals from 
transgenic livestock. Tib. Tech. 5:20-24.
Coghan, A. 1991. Dutch lack appetite for genetically 'altered' foods. New Sci-
entist. August 17, p.9.
Congressional Record-Senate. 1991. Letter to Hon. Mark O. Hatfield from 
H.F. Manbeck, Jr., Assistant Secretary and Commissioner of Patents and 
Trademarks. June 13, p.S7817.
Durning, A. and H. Brough. 1991. Taking stock: Animal farming and the envi-
ronment. World Watch Institute, Washington, DC.
Dodds, W.J. 1990. Vaccine, drug and chemical-mediated immune reactions 
in purebreds challenging researchers. DVM Magazine. December, pp. 
41-42.
Fackelmann, K.A. 1990. Engineered rats reveal arthritic surprise. Science 
News. December, p. 357.
Federal Register. 1991. Agricultural research service intent to grant and exclu-
sive license to animal biotechnology. January 10,56 (7):990.
Feinstein, P. and J.D. Miller. 1989. Public perception of biotechnology: Is the 
glamor gone? In Biotechnology Seminar Series Academic Year 1988-1989: 
Summary Reports. Tufts Center for Animals and Public Policy, Tufts 
School of Veterinary Medicine, North Grafton, MA. pp. 12-14.
Fischetti, M. 1991. Feast of gene-splicing down on the fish farm. Science.
253: 512-13.
Ford, J. 1988. This little pig rushed to market. New Scientist. April 28, p. 27.
Fox, J.L.1991. Scope proposal goes another round. Bio/Technology. 9:603.
Fox, M.W. 1992. Superpigs and Wondercorn. Lyons and Burford, NY.
Fox, M.W. 1990. The cattle threat. The Humane Society of the United States 
News. Spring, pp. 24-27.
Gendel, S.M. and A.D. Kline, D.M. Warren and F. Yates, eds. 1990. Agricul-
tural bioethics: Implications of agricultural biotechnology. Iowa State Uni-
versity Press, Ames, Iowa.
Genetic Engineering News. 1991. Transgenic mice development for sickle-cell 
anemia. June, p. 34.
Holden, C. 1988. Japanese views on science compared to U.S. attitudes. Sci-
ence. 240:277.
Holden, C. 1991. Superchicken. Science. 253:265.
Hubbard, R. and S. Krimsky. 1988. The patented mouse. GeneWatch. 5:6-7.
Kraemer, D.C. and J. W. Templeton. 1990. Genetically engineered resistance 
in mammals. In Veterinary Perspectives on Genetically Engineered Ani- 
mals. American Veterinary Medical Association. Schaumburg, Illinois, 
pp. 48-53.
Animal Biotechnology/ Opportunities & Challenges
Mackenzie, D. 1991. People’s poll shows confusion over biotechnology, New 
Scientist. July 13, p.14.
Manci, W.E. 1989. Researchers continue work in transgenic catfish and 
salmon. Ag. Biotech. News. Sept/Oct. p. 22.
Mercier, J. C. 1987. Genetic engineering applied to milk-producing animals:
Some expectations. In Commission of the European Communities Ani-
mal Husbandry Research Program, Exploiting New Technologies in Ani-
mal Breeding. Oxford Univ. Press, Oxford, pp. 122-31.
Moffat, A.S. 1991a. Three little pigs and the hunt for blood substitutes. Science.
253: 33.
Moffat, A.S. 1991b. Bumper transgenic plant crop. Science. 253:33.
Murray, J.D. and Rexroad, C.E. Jr. 1991. The development of sheep express-
ing growth promoting transgenes. In NABC Report 3 Agricultural Bio-
technology at the Crossroads. J. Fessenden MacDonald, ed. National Agri-
cultural Biotechnology Council. Ithaca, NY. pp. 251-263.
New York Times. 1990. New prospects for gene-altered fish raise hopes and 
alarm. November 27, p. C4.
New Scientist. 1992. Australian sheep let their hair down. January 4, p 8.
Phelps, A. 1989. Researchers from the Netherlands design cow for production 
of human-like milk. Feedstuffs. September 4, 81:37.
Phelps, A. 1991. EC plans to end socio-economic animal drug criteria.
Feedstuffs. July 15, p. 25.
Schanbacher, F.L. 1990. Molecular farming: Current status and prospects. In 
Veterinary Perspectives on Genetically Engineered Animals. American Vet-
erinary Medical Association. Schaumburg, Illinois, pp. 54-57.
Scherer, R. 1991. Peelable wool not shear fantasy. The Christian Science Moni-
tor. April 17, p. 12. 61
Schmickly, S. 1991. Don’t have just any cow-Clone a better bossy. The Wash-
ington Times. April 19, p. B7.
Slater, D.W. 1990. Genetically engineered disease resistance in poultry. In
Veterinary Perspectives on Genetically Engineered Animals. American Vet-
erinary Medical Association. Schaumburg, Illinois, pp. 44-47.
Watts, S. 1990. Drugs industry turns animals into ‘bioreactors’. New Scientist.
April 14, p. 26.
Watts, S. 1991. A matter of life and patents. New Scientist. January 12, pp. 56-61.
Wheale, P. and R. McNally, eds. 1990. The Bio-Revolution: Cornucopia or 
Pandora’s Box? Pluto Press, London and Winchester, Massachusetts.
The New Creation
